You searched for "prostatic apex"

137 results found

Nomograms – is it hide and seek?

Everyday new decision-making aids are being developed due to various advances in software technology. This article from the UK makes very interesting reading. The word ‘nomogram’ is derived from the Greek word translated as ‘law line’ or ‘alignment chart’. The...

RARP – novel uroflow stop test

More and more centres are doing robotic assisted radical prostatectomy (RARP) surgery for cancer of the prostate .This study from Montreal, Canada describes a simple and novel test to predict recovery of urinary continence after RARP. The uroflow stop test...

Metabolic syndrome and prostate cancer recurrence in a veterans’ cohort

This study explored the relationship between metabolic syndrome and localised prostate cancer recurrence in patients who had received active treatment (external beam radiation therapy – EBRT, radical retropubic prostatectomy – RRP, or brachytherapy). The definition of metabolic syndrome adopted was...

Penile clamp device – a new indication?

This study originates from New Zealand and looks at men affected by post-prostatectomy incontinence (PPI). These patients are difficult to manage with the options of further surgery, indwelling catheters or pads. The aim of this questionnaire study (IIQ 7) was...

Focal therapy trials

Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...

Demanding cases or nightmares in uro-oncology? Jan/Feb 2023

Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Moving pictures

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). Those of you who occasionally wander (virtually of course) into the online Museum...

Management of Prostate Cancer: A Multidisciplinary Approach

This is an excellent textbook which comprehensively covers the vast field of prostate cancer. The editors, who have co-ordinated phase III European Organisation for Research and Treatment of Cancer (EORTC) trials, have brought together a large array of well-known international...

ASAP: is a repeat biopsy necessary?

This study examined the validity of current US and European guidelines on the management of patients diagnosed with atypical small acinar proliferation (ASAP). Current guidance states that these patients should undergo repeat biopsy within three to six months due to...

Read all about it Mar/Apr 2021

Read all about it... It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking...

Focal therapy for prostate cancer – ready for prime time?

The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...